Skip to Main Content

SAN FRANCISCO — It took only a single, one-hour meeting in a Starbucks to convince venture capitalist Robert Nelsen that he was going to invest in the company being built by machine-learning whiz Daphne Koller. “She’s just an amazing force of nature,” said Nelsen, who invests for ARCH Venture Partners.

Koller’s company, Insitro, in a matter of months raised over $100 million from big-name investors including ARCH, Foresite Capital, Andreessen Horowitz, and the firm that manages Jeff Bezos’ personal VC investments. (Koller refers to Bezos by his first name.) Now, it’s time for the next step. On Tuesday, the giant drug maker Gilead Sciences said it would pay Insitro $15 million — and up to $1 billion more down the line if it meets certain goals — for help in developing drugs to treat a common liver disease. It is the South San Francisco-based company’s first deal with a drug maker, and offers a test of whether artificial intelligence can remake drug development.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • Do I believe in 50-100 years problems in biology and medicine will be solved in silico? yes

    Do I believe all the buzz around AI, machine learning is because we are at a stage where it can actually do that? Not at all

    Culprit, she has been working on it for 20 years, and I doubt she has achieved anything meaningful in that area, or there is no evidence of it
    There is simply not enough knowledge, consistent experimental data, and I guess, good enough algorithms to pull it off

Comments are closed.